Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzupacap sarotalocan in primary indeterminate lesions and small choroidal melanoma
NCT04417530Phase 2Completed
- Sponsor
- Aura Biosciences, Inc.
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of belzupacap sarotalocan in choroidal melanoma, sponsored by Aura Biosciences, Inc.. Started Aug 2020; status: completed.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanoma
Beyond the preview
Go deeper on NCT04417530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417530.